The psychedelic biotech sector (as proxied by PSYK ETF or equivalent index) will show no positive return from May 2026 levels through June 2, 2026, absent a confirmed FDA approval or Phase 3 trial success announcement.

The psychedelic biotech sector—tracked by the PSYK ETF (an exchange-traded fund that holds psychedelic drug companies)—will show no gain from May through early June 2026 unless the FDA (the US drug regulator) approves a psychedelic drug or a company announces success in a late-stage trial. Over just 30 days, the sector is likely to stay stuck without major good news.

Original resolve date of June 2, 2026 is only ~30 days away, making this a near-term market call. Sharpened with a specific index proxy. Institutional pressure and lack of near-term catalysts support the bear case over 30 days. However, 30-day windows are highly volatile; macro risk-on rallies can override sector fundamentals. Confidence trimmed to reflect short-window noise.